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Abstract
Background: The worldwide neglect of immunotherapeutic products for the treatment of snakebite has resulted in a critical
paucity of effective, safe and affordable therapy in many Third World countries, particularly in Africa. Snakebite ranks high
among the most neglected global health problems, with thousands of untreated victims dying or becoming permanently
maimed in developing countries each year because of a lack of antivenom—a treatment that is widely available in most
developed countries. This paper analyses the current status of antivenom production for sub-Saharan African countries and
provides a snapshot of the global situation.
Methods: A global survey of snake antivenom products was undertaken in 2007, involving 46 current and former antivenom
manufacturers. Companies producing antivenom for use in sub-Saharan Africa were re-surveyed in 2010 and 2011.
Results: The amount of antivenom manufactured for sub-Saharan Africa increased between 2007 and 2010/11, however
output and procurement remained far below that required to treat the estimated 300,000–500,000 snakebite victims each
year. Variable potency and inappropriate marketing of some antivenoms mean that the number of effective treatments
available may be as low as 2.5% of projected needs. Five companies currently market antivenom for sale in Africa; three
others have products in the final stages of development; and since 2007 one has ceased production indefinitely. Most
current antivenom producers possess a willingness and capacity to raise output. However inconsistent market demand,
unpredictable financial investment and inadequate quality control discourage further production and threaten the viability
of the antivenom industry.
Conclusion: Financial stimulus is urgently needed to identify and develop dependable sources of high-grade antivenoms,
support current and emerging manufacturers, and capitalise on existing unutilised production capacity. Investing to ensure
a consistent and sustainable marketplace for efficacious antivenom products will drive improvements in quality, output and
availability, and save thousands of lives each year.
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Introduction
Snakebite is a significant social and economic problem in many
developing countries, however its victims rank among those most
neglected by global health campaigns. Snakebite was recognised
by the WHO as a Neglected Tropical Diseases in 2007, and
antivenom – the only specific treatment for systemic envenoming -
remains largely inaccessible to hundreds of thousands of snakebite
victims around the world. Since its introduction and continued
refinement throughout the twentieth century, antivenoms have
saved countless lives [1]. Although readily available in wealthy
countries and able to reduce mortality rates to less than 1% [1–3],
sources of effective, safe and affordable antivenom in low-income
countries, where the incidence of snakebite is greatest, are highly
variable. Whilst good quality products do exist in some developing
countries its procurement is often inadequate, leaving snakebite
victims without access to proper treatment. Quantifying the gap
between what is currently available and what is needed is a critical
step towards developing effective solutions to this problem. This
study provides a contemporary overview of global antivenom
production, focusing particularly on the antivenom market in sub-
Saharan Africa.
1. The rise and fall of antivenom
Since Edward Jenner’s controversial inoculation of James
Phipps with cowpox in 1796, immunotherapy has developed into
a diverse industry [4]. Calmette’s groundbreaking work with
equine antiserum resulted in the first, unrefined antivenom in
1894. Pope’s improvements to antivenom refinement in the 1930s
were another major step forward in safety and potency of
antivenom. Unfortunately, further advances since then have been
www.plosntds.org 1 June 2012 | Volume 6 | Issue 6 | e1670limited. Despite snakebite being over-represented in morbidity and
mortality tables [5], investment in this type of immunotherapy has
not been characterised by the same level of publicity or resolve
that has characterised vaccine production or monoclonal antibody
research. This under-recognition of bites and stings as major
medical and social problems, and snakebite’s association with
poverty, have contributed to the current antivenom crisis [6].
The introduction of antivenom to Africa in the 1950s heralded a
decline in morbidity and mortality from snakebites that led to its
widespread use and production. Sadly, over the last 30 years,
production of this life-saving medication has been neglected by
governments and non-government organisations, and abandoned
by some manufacturers [7]. The 1970s and 1980s were char-
acterised by a decline in the sale of antivenom in Africa due to
growing neglect and prohibitive costs [8]. By 1998, it was estimated
that fewer than 100,000 vials of antivenom were available across
Africa, constituting less than 25% of the amount needed [9]. A
number of recent publications state the availability of antivenom in
Africa has reduced to ,1% of what is needed, or ‘‘,20,000 vials
reduced from ,250,000 doses/year 25 years ago’’ [10]. The WHO
has estimated that antivenom supply failure in Africa is imminent
[11], which is further compounded by the presence of non-specific
or fake products, inappropriate clinical use and poor community
awareness of the benefits of antivenom [12–14].
Methods
Data for this paper was collected from primary and secondary
sources, including interviews, surveys, product inserts and
literature searches. Market research surveys were sent to
representatives from 46 known antivenom manufacturers in
2007. Previous, current and future producers for sub-Saharan
African markets were again contacted in 2010 and 2011. One
current and one future company did not respond in 2010/2011.
Companies responded with information regarding the following:
N quantity and type of antivenom produced, including number
of unsold vials;
N average number of snake antivenom vials required to
successfully treat a moderately severe snake envenomation;
N countries where antivenom is marketed;
N wholesale cost of antivenom;
N existing spare production capacity;
N quality control and regulatory standards;
N profitability of antivenom products; and
N attitudes about the use, availability and sustainability of
antivenom.
Calculations regarding the number of vials that constitute an
‘‘effective treatment’’ are based on company information and
product inserts for an average, or moderately severe, envenom-
ation. Independent testing of potency and proteomic analysis to
validate the species of origin was outside the scope of this study,
although verification was sought through literature reviews.
Results
1. Epidemiological estimates of antivenom requirement
The global incidence of clinically significant snakebite has been
calculated to be between 421,000 and 2.5 million annually
[15,16], with up to 500,000 occurring in Africa each year
[10,17,18]. Inadequate record keeping and limited primary
epidemiological studies makes accurate assessment difficult, and
most authors concur that estimates of snakebite incidence under-
represent the problem. Up to 20–70% of victims in some regions
do not present to hospital because they are either unaware
treatment is available, cannot afford it, or instead utilise ineffective
traditional healing methods [19–21]. However a recent metaana-
lytical study of reported data concluded that probably 314,000
snakebites occur in Africa annually [22]. The rate of snakebite in
sub-Saharan Africa varies between 150–250/100,000 population
[23–25], with a peak incidence in some regions in Nigeria of 497/
100,000 [26].
At least 20,000 deaths each year are attributed to snakebite in
Africa [17], although this is also considered conservative. The
recorded annual mortality in Nigeria, Senegal and Kenya is
between 2–16/100,000 population, and across Africa the case
fatality rates from untreated snakebite ranges from 4% to 24%
[27–30]. The WHO estimates that 10% of envenomings results in
serious, non-fatal sequelae, while other reports have stated that
12,000–14,000 amputations and other sequelae result from
snakebites in Africa annually [19,31,32]. Other debilitating
morbidities result from the neurotoxic, coagulopathic or necrotic
components of different venoms, with clinical effects ranging from
chronic ulceration, osteomyelitis, chronic renal failure, endocrine
disorders, paralysis, stroke and blindness.
2. Current African antivenom market
a. Manufacturers (table 1). Between 2007 and 2010/11, six
manufacturers sold antivenom for use in sub-Saharan Africa,
although one has now ceased producing African antivenom
indefinitely and another now only manufacturers antivenom to
order after a lack of demand forced a temporarily hiatus of
production in 2010. Three other institutions are developing
antivenom against African snake species that have either recently
been licensed or are in the final stages of development. Data on the
Author Summary
Antivenom is the only specific treatment for systemic
envenoming from snakebite, but remains unavailable to
thousands of snakebite victims around the world. A cycle
of inconsistent and low market demand, sub-optimal
utilisation, rising costs and reduced output of antivenoms
have resulted from long term under-investment in
procurement and quality regulatory programs. This study
provides a contemporary overview of the African anti-
venom market within the context of the global market.
Globally, 35 companies sold at least 4 million vials of
antivenom in 2007. Five companies had established
African antivenom markets in 2010/11; three other
institutions have antivenoms for Africa in development;
and another ceased production indefinitely. Between 2007
and 2011, production of sub-Saharan African antivenoms
rose from 227,400 to at least 377,500 vials, constituting
,83,000 effective treatments for moderate envenomings.
However, recent reports have identified that some
products, which comprise up to 90% of the total
antivenom supply in sub-Saharan Africa, may lack efficacy
or specificity against relevant snake species. Despite this,
revenues from antivenom marketed in sub-Saharan Africa
increased from $6.6 million in 2007 to $10.3 million in
2010/11. The average cost of a stated effective treatment
in 2010/11 was $124, and the price of antivenom is
inversely proportional to the amount produced. Combined
unutilised production capacity far exceeds the total
projected antivenom needs for Africa.
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is either not yet available or for experimental purposes only.
Companies are based in the United Kingdom, France, South
Africa, India, Mexico, Costa Rica and Brazil, with only one
classified as ‘‘big pharma’’.
A further three groups based in Egypt, Saudia Arabia and Iran
produce antivenom against snake species found in West Asia and
the Arabian peninsula, which may have efficacy against some
North African snake species. Owing to their ‘‘off-label’’ nature for
use against continental African snake species, these were not
included in the final analysis. Another organisation, based in
Colombia, appears to have suspended development of a pan-
African antivenom after conducting preclinical work in 2003.
b. Antivenom output and capacity. Producers of sub-
Saharan African antivenom had a combined annual output of at
least 377,500 vials in 2010/2011, equating to approximately
83,000 complete treatments for moderate envenoming, based on
manufacturers’ recommended doses (table 2). By comparison,
227,400 vials of sub-Saharan African antivenom were marketed to
African countries in 2007, providing just over 54,000 average
treatments (table 3). In 2007, manufacturers reported a combined
excess supply of more than 26,000 vials of unsold African
antivenom. By 2010 no manufactured antivenom was unsold,
however significant unutilised production capacity was reported by
5 of the 8 current producers, including two with manufacturing
facilities and quality control procedures regulated by the European
Medical Agency (EMEA). If utilised, this combined capacity could
produce enough antivenom to treat 600,000 patients and save
thousands of lives.
c. Antivenom quality. It is evident from product inserts and
literature reviews that the potency of antivenom sold in sub-
Saharan Africa varies widely. The average number of antivenom
vials required to achieve effective neutralisation of a moderate
envenoming, based on manufacturers’ recommended doses, is 4.5
vials (range 1 to 12 vials). Doses for severe envenomings can be
several times greater. Whilst proven effective antivenom products
against African snake species do exist, it is highly concerning to
note that recent peer-reviewed evaluations and published personal
reports have indicated that two dominant products in the African
market, which account for up to 90% of the total output, lack
efficacy against some snake species to which they are targetted
[2,12,33–35]. The actual number of effective antivenom treat-
ments available in Africa, therefore, is potentially only a fraction of
the 83,000 stated above, and may cover as little as 2.5% of the
estimated need.
d. Antivenom cost. The wholesale cost of antivenoms for
sub-Saharan Africa ranged from $18 to $200 per vial. The
corresponding cost per effective treatment, using recommended doses,
was $55 to $640, with an average cost of $124. Total company
revenues from these products increased from $6.6 million in 2007
to approximately $10.3 million in 2010/11. The two largest
manufacturers accounted for almost $8.4 million (81.5%) of
revenues, despite recent concerns about the suitability of their
products for use in some African markets.
e. Antivenom formulation. Of the 8 current and pending
producers of sub-Saharan African antivenoms, 6 manufacture
solely polyspecific products, one produces only monospecific, and
one produces both polyspecific and monospecific antivenoms. One
Table 1. Recent and current sub-Saharan African antivenom manufacturer.
Company, country of origin Antivenom type Venoms used in immunisation Countries antivenom is available
MicroPharm, United Kingdom Mono; ovine; liquid (10 ml);
intact IgG
Echis ocellatus, with cross specificity for
other Echis species
Nigeria
Sanofi Pasteur, France Poly; equine; F(ab)92; lyophilised,
(10 ml);
Bitis gabonica, Bitis arietans, Echis
leucogaster, E. ocellatus, Naja haje, N.
melanoleuca, N. nigricollis, Dendroaspis
polylepis, D. viridis, D. jamesoni
West Africa, East Africa
South African Vaccine Producers, South
Africa
Two6mono; one6poly; equine,
F(ab)92); lyophilised or liquid
(10 ml)
Dispholidus typus (mono); Echis ocellatus/
carinatus (mono); Bitis arietans, B.gabonica,
Haemachatus haemachatus, Dendroaspis
angusticeps, D. jamesoni, D. polylepis, Naja
nivea, N. melanoleuca, N. annulifera, N.
mossambica (poly)
South Africa, other African countries
occasionally
VINS Bio, India Poly; equine; liquid (10 ml) or
lyophilised; .20–25 LD50
Naja melanoleuca, N. nigricollis, N. haje,
Dendroaspis polylepis, D. viridis, D. jamesoni,
Bitis gabonica, B. arietans, Echis leucogaster,
E. carinatus#; Daboia russelli#,
Kenya, Nigeria, Ghana, Burkina Faso,
Angola, Mozambique, Sudan
Bharat Serums and Vaccines, India Poly; F(ab)92 equine; lyophilised or
liquid (10 ml);
Bitis gabonica, B. arietans, B. nasicornis,
Dendroaspis jamesonii, D. polylepis, D.
angusticeps, Echis carinatus#,Naja nivea,
N. nigricollis, N. haje, N. Melanoleuca
Ghana, Nigeria, Kenya, Benin, Burkina
Faso, Sudan
Serum Institute of India, India* (now
discontinued)
Poly; equine; lyophilised (10 ml) Bitis, Echis, Dendroaspis, Daboia russelli# Ghana, Tanzania, Ethiopia, Kenya, Sudan
Instituto Bioclon, Mexico, N/A Poly; equine; F(ab)92; lyophilised Bitis arietans, B. gabonica, Echis ocellatus, E.
Pyramidum, E. leucogaster, Naja naja, N. haje,
N. nigricollis, N. pallida, Dendroaspis polylepis,
D. Viridis
West Africa; Post clinical trials; [44]
Instituto Clodomiro Picado, Costa Rica, N/A Poly; equine; liquid; intact IgG Echis ocellatus, Bitis arietans, Naja nigricollis West Africa; Post clinical trials; [2]
Instituto Butantan, Brazil, N/A Poly; Equine, F(ab)92, liquid. Bitis arietans, B. nasicornis, B. rhinoceros,
Naja malanoleuca, N. Mossambica
Mozambique; in clinical trials [41]
(* manufacturer has now ceased antivenom production; # not an African species; poly=polyspecific; mono=monospecific; N/A=not yet available).
doi:10.1371/journal.pntd.0001670.t001
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antibodies purified with caprylic acid, while the remainder
manufacture F(ab)92 products. One company utilises ovine
antisera instead of equine, and 6 offer lyophilised products.
3. Global antivenom market
a. Manufacturers. In 2007, 46 one-time antivenom manu-
facturers across 28 countries were surveyed and 35 reported
current production of at least one type of snake antivenom for
commercial, government or research purposes. Eleven organisa-
tions listed in various media as antivenom manufacturers either no
longer produce snake antivenom or did not respond to the survey.
Twenty-four of the 35 organisations producing antivenom operate
on a commercial basis; 6 were purely government facilities
manufacturing non-commercial antivenom for domestic purposes;
and 5 companies did not provide financial data.
b. Antivenom output and capacity. Total global snake
antivenom output by surveyed companies exceeded 4 million vials,
although this equated to fewer than 600,000 effective treatments.
This is well below the WHO’s worldwide estimated requirement of
at least 2 million treatments per year. Globally, twelve manufac-
turers reported having capacity to increase volume, which if
realised could potentially double the current output.
c. Antivenom quality and formulation. As with the
antivenoms in Africa, many commercially available antivenoms
are associated with highly variable potency, ranging from 1 to .30
vials required to complete an effective treatment. A majority of
products were produced using F(ab)92, and only 3 manufacturers
reported using Fab or intact IgG.
d. Antivenom cost. In 2007 wholesale prices for individual
antivenoms across the global range of products ranged from $8 to
$1338. The cost of treatment based on manufacturer recom-
mended doses was calculated to be between $40 and $24,000.
However case reports indicate that the number of vials required to
successfully treat severe envenoming with some products may
exceed the recommended amount [36,37], with associated
wholesale costs of over $35,000 per treatment [38] and even
higher retail costs. Total company income from worldwide
antivenom sales amounted to more than $60 million, and only
two groups had annual antivenom sales exceeding $10 million.
There is a clear relationship between wholesale cost of
antivenom and throughput (Figure 1), which has important
implications for strategies seeking to increase the amount of
antivenom produced globally. It was estimated by one company
that costs could be reduced 5-fold from an 8-fold increase in
output. Another company reported that doubling production
would only increase costs by 10% and could potentially halve
antivenom price. However, the retail price of antivenom is also
heavily influenced by the market’s ability to pay for it. On a per
vial basis, antivenom developed for use in high-income countries is
disproportionately more expensive, represented by the two out-
lying plot points in Figure 1.
4. Attitudes to future antivenom production
All companies currently producing antivenom for sub-Saharn
Africa indicated a willingness to increase output should market
demand improve. Manufacturers identified factors that prevented
them from raising production, despite a willingness to do so.
Whilst not all manufacturers listed the same reasons, there was
some concordance and the responses below have been listed in
descending order of frequency:
N Lack of consistent market demand for antivenom products;
N Inconsistencies with manufacturers receiving payment.
N Corruption within some global markets and government
agencies;
N Threats from black market re-sale of antivenom products;
N Lack of appropriate venom for immunogen preparation,
N A lack of certainty regarding appropriate distribution of their
products;
N Inappropriate clinical use of antivenom products;
N Lack of adequate animals for raising antisera; and
N High costs of maintaining livestock for antivenom production;
Discussion
This survey of antivenom manufacturers highlights the paucity
of antivenom products for sub-Saharan Africa and the unhelpful
variability that exists within the current industry. It also illustrates
that despite the exodus of manufacturers in the 1970s and 1980s,
willing producers do exist and they possess substantial unutilised
production capacity. Unfortunately, inadequate government and
non-government funding for procurement and regulatory over-
sight restrains production of commercial antivenom. This lack of
investment is not only the reason for the current crisis in
antivenom availability, but also represents the greatest challenge
to future improvements in quantity and quality.
Although inexpensive and efficacious antivenoms do exist, and
compelling moral and legal arguments advocate increased
purchase and distribution [39,40], a lack of funding for antivenom
Figure 1. Antivenom price v output. Economies of scale mean that the cost per ampoule decreases as throughput increases.
doi:10.1371/journal.pntd.0001670.g001
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vicious cycle responsible for the decline in production and use over
the last 30 years (figure 2). This cycle has also contributed to
conditions that have allowed lesser quality products and inappro-
priate marketing to emerge. The arrival of new manufacturers and
the presence of spare capacity within some current facilities
provide hope, but uncertain market conditions and inadequate
financial support will continue to restrict growth of trustworthy
antivenoms.
This cycle is a variation on that proposed by Stock et al in 2007
[9], and demonstrates the importance of future financial stimulus in
reinvigorating competition and viability of the antivenom market.
Inadequate financing within the antivenom industry is the major
factor underpinning its decline over the last 40 years, and strategies
to solve this crisis must recognise and unwind the economic and
commercial drivers on both sides of the supply and demand
equation. It is unrealistic to expect that pharmaceutical companies
will commit to long-term production of antivenom for an
inconsistent and unreliable market that is starved of investment.
Even if greater volumes of appropriate antivenom could be
produced, without adequate subsidisation it will be priced out of
range for most snakebite victims living in underprivileged rural and
remote areas. Similarly, corporate executives and regulatory bodies
must also accept that there exists a moral imperative for them to
contribute their expertise and capabilities, and that existing business
models and production frameworks may be inappropriate for the
supply of humanitarian products to developing countries.
Encouragingly, there has been a small increase in financial
support for the development and procurement of new African
antivenoms between 2007 and 2010. Whilst the .$60 million in
global antivenom revenue and $10.3 million from African
antivenom sales are small by pharmaceutical standards, this
represents valuable investment and an encouraging base from
which the industry can grow. Better utilisation of spare production
capacity and improved economies of scale will produce greater
yields, reduce costs, increase revenues and further enhance the
commercial viability of antivenoms.
The second major problem eroding the antivenom market is the
lack of accountability in quality standards. Possessing the capacity
to produce vast amounts of antivenom for sub-Saharan African
communities is meaningless if the products are poorly made and
ineffective against the snakes in those regions. A current lack of
interest, insufficient investment and poor competition are allowing
unscrupulous behaviours within the marketplace to go unchecked.
Given the ongoing severe shortage of antivenom and the
continuing high incidence of envenoming, it is not surprising that
opportunistic manufacturers seek to fill the void. The advent of
seemingly inexpensive, but low quality or inappropriate anti-
venoms with poor neutralising ability, not only compromises the
reputation of antivenoms in general but also drains important
financial resources away from proven snakebite treatment
programs and products. Some manufacturers have cited this
uneven playing field as a key impediment to future innovation and
productivity. Nevertheless, the very high volume output by some
manufacturers of alleged inappropriate products still make them
key players in the antivenom industry, and potentially integral to
future strategies for increasing output of higher quality products.
Improving standards and maximising efficiencies ought to be the
common goal for all manufacturers.
The three groups with emerging new African antivenoms
provide hope for the future [41–44], however ensuring that these
products, as well as existing antivenoms, are of sufficient quality to
be incorporated into a properly funded and sustainable market is
paramount [8]. The final quality control checkpoint for all
antivenoms entering a country should be the national regulatory
authorities. It is essential that NRAs are adequately resourced and
transparent to ensure the integrity and robustness of their
mechanisms are above reproach. Linking funds for antivenom
procurement to improved quality control and assurance measures
would enhance the crucial role of local regulatory bodies and
incentivise the maintenance of minimum standards.
Antivenom’s usually rapid and curative effects make it a highly
cost-effective intervention [40], and together with snakebite’s
surpassing morbidity and mortality [6], ought to attract attention
from global health funding bodies. If improved efficiencies,
technical support and collaboration within the antivenom industry
were achieved, the cost of an effective antivenom treatment would
fall below the current average of $124, and may ultimately be
significantly less than $100. Supplying sufficient quantities of
antivenom to the whole of Africa at that price would require an
annual input of less than $30–$50 million, which is considerably
lower than the budgets for many other global health programs.
Leadership and support from groups such as the Global Snakebite
Initiative and the World Health Organisation may help to secure
essential funds from donors and provide important coordination,
transparency and accountability. It will also help to recruit and
Figure 2. The self-perpetuating cycle responsible for the decline in antivenom production in sub-Saharan Africa. Inadequate financial
support for antivenom production and variable quality have catalysed the collapse of the antivenom market, which is now characterised by deficient
supply, deficient quality control, rising prices and poor profitability.
doi:10.1371/journal.pntd.0001670.g002
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effective and appropriate antivenoms.
The declining availability of high quality antivenom in sub-
Saharan Africa is a real and unnecessary tragedy, and constitutes a
major neglected global health concern. The amount of suitable
antivenom marketed in these countries has fallen to crisis levels,
representing only a fraction of the amount required. Although
recent output of antivenom for Africa has increased, and the
number of manufacturers able to boost production is growing,
inadequate financial support and market uncertainty continue to
suppress growth and compromise quality standards. The provision
of sufficient funds to identify satisfactory antivenoms, maintain
quality control, maximise efficiencies and increase procurement is
desperately needed to break the vicious cycle that currently
constrains the antivenom industry. The mechanisms to achieve this
are realistic and available; science, business and government must
collaborate to secure a brighter future for snakebite victims in
developing countries. Only then will the goal of providing effective,
safe and affordable antivenoms to all who need them, be realised.
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